Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.35 HKD | +0.83% | +3.42% | +5.09% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.09% | 1.99B | - | ||
-3.79% | 184B | C+ | ||
-0.84% | 108B | C | ||
-3.75% | 67.8B | A | ||
+3.45% | 51.05B | B- | ||
+9.04% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+3.66% | 26.59B | A- | ||
+3.21% | 26.78B | B | ||
+15.23% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6826 Stock
- Ratings Shanghai Haohai Biological Technology Co., Ltd.